Oral CBP-0276 for early psoriatic arthritis
Part of Bones, joints & muscles, Skin clinical trials.
This study tests an oral investigational pill (CBP-0276) called an oral therapy for psoriatic arthritis. The goal is to see if it reduces joint pain, swelling, and psoriasis symptoms better than a placebo (inactive pill).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have psoriatic arthritis (PsA) symptoms for more than 6 months but less than 12 months
- You have at least 3 tender and 3 swollen joints (active disease)
- You have plaque psoriasis now or have had it in the past
- Typical arthritis or psoriasis medications (NSAIDs or csDMARDs) have not helped enough
- You do not have other serious inflammatory or autoimmune diseases, active infections, or cancer (within last 5 years)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This study tests an experimental drug called JNJ-88545223 to see if it can reduce joint pain, swelling, and skin plaques in people with active psoriatic arthritis. It may help if you have both joint symptoms and psoriasis.
This trial tests an oral medication, D-2570, for people with active psoriatic arthritis. It aims to see if the drug can reduce joint pain and swelling.
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
This trial tests an experimental oral medication called TQH3906 for people with active psoriatic arthritis (PsA), a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if TQH3906 is safe and effective in reducing arthritis symptoms.
This trial tests an investigational drug (DDY391) in people with moderate to severe psoriatic arthritis. The goal is to see how well it works and if it is safe, which might help reduce joint pain and skin symptoms.
Hear when a new Arthritic Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.